<DOC>
	<DOCNO>NCT02118896</DOCNO>
	<brief_summary>The purpose study offer patient participate one phase II PK phase III study FK506E ( MR4 ) possibility continue FK506E ( MR4 ) commercial availability drug record long term efficacy safety data .</brief_summary>
	<brief_title>Study Ascertain Prolonged Release Tacrolimus ( FK506E - MR4 ) Safe Effective When Used Long Term Combination With Other Immunosuppressive Drugs Patients Who Have Received Transplant</brief_title>
	<detailed_description>The objective study asses safety effecicacy FK506E ( MR4 ) long-term treatment transplant recipient . Only patient participate one phase II PK phase III study FK506E ( MR4 ) receive least one dose study medication enrol .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients already participate previous phase II pharmacokinetic phase III study FK506E ( MR4 ) . Patients capable understanding purpose risk study , fully inform give write informed consent participate study . Pregnant woman nurse mother . Women unwilling unable use adequate contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>FK506E</keyword>
	<keyword>MR4</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Heart Transplantation</keyword>
</DOC>